megestrol acetate has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheewakriangkrai, R; Euathrongchit, J; Thaikla, K; Thongprasert, S | 1 |
Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H | 1 |
Gatzemeier, U; Heckmayr, M | 1 |
2 trial(s) available for megestrol acetate and Carcinoma, Non-Small Cell Lung
Article | Year |
---|---|
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Megestrol Acetate; Mesna; Middle Aged; Protective Agents; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
Megestrol acetate in cachectic patients with advanced bronchogenic cancer.
Topics: Appetite; Cachexia; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Megestrol; Megestrol Acetate; Prospective Studies; Weight Gain | 1990 |
1 other study(ies) available for megestrol acetate and Carcinoma, Non-Small Cell Lung
Article | Year |
---|---|
Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Paclitaxel; Survival Analysis | 2002 |